Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan and Cisplatin vs Etoposide and Cisplatin in Limited-Stage Small-Cell Lung Cancer
NCT00144989Phase 3Completed
- Start
- Sep 2002
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan in small cell lung cancer (SCLC) (2 arms). Primary endpoint: Overall Survival. Started Sep 2002; status: completed.
02
Drugs
irinotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00144989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00144989.